Targeted Genomics, LLC

Targeted Genomics is a family-owned molecular diagnostics company specializing in celiac disease genetic risk assessment. The company develops and offers the GlutenID™ test, an FDA-cleared at-home saliva-based genetic test that identifies HLA-DQ2 and HLA-DQ8 genotypes associated with celiac disease risk. The test is designed as a universal triage tool to distinguish at-risk individuals from those who can rule out celiac disease. Founded and led by Dr. Shelly Gunn, MD, PhD, a board-certified pathologist with expertise in molecular diagnostics and genomic analysis, Targeted Genomics partners with PacificDX, a CAP/CLIA-certified laboratory in Irvine, CA, for sample processing and analysis. The company also offers complementary celiac disease testing services including the Celiac Disease Panel (antibody testing) and CeliacDx Consult (expert pathology review). Testing workflow involves at-home saliva collection via cheek swab, mail-in sample submission with prepaid shipping, laboratory processing, and secure email delivery of results with actionable next steps. The company maintains strict privacy controls—only HLA genotypes are interrogated, genomic data is stored securely for two years per CAP requirements, and data is never sold or shared with third parties. Targeted Genomics serves consumers, families with celiac history, and healthcare providers seeking efficient genetic screening to guide subsequent antibody and biopsy testing in celiac disease diagnosis.